Article
Revista Española de Medicina Nuclear e Imagen Molecular (English Edition)
array:24 [ "pii" => "S2253808918300764" "issn" => "22538089" "doi" => "10.1016/j.remnie.2018.10.006" "estado" => "S300" "fechaPublicacion" => "2019-07-01" "aid" => "1020" "copyright" => "Sociedad Española de Medicina Nuclear e Imagen Molecular" "copyrightAnyo" => "2018" "documento" => "article" "crossmark" => 1 "subdocumento" => "sco" "cita" => "Rev Esp Med Nucl Imagen Mol. 2019;38:260-1" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "Traduccion" => array:1 [ "es" => array:19 [ "pii" => "S2253654X18301598" "issn" => "2253654X" "doi" => "10.1016/j.remn.2018.09.003" "estado" => "S300" "fechaPublicacion" => "2019-07-01" "aid" => "1020" "copyright" => "Sociedad Española de Medicina Nuclear e Imagen Molecular" "documento" => "article" "crossmark" => 1 "subdocumento" => "sco" "cita" => "Rev Esp Med Nucl Imagen Mol. 2019;38:260-1" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:2 [ "total" => 80 "formatos" => array:2 [ "HTML" => 39 "PDF" => 41 ] ] "es" => array:11 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Imágenes de interés</span>" "titulo" => "Efecto positivo del tratamiento con Actinio 225-PSMA sobre el estado funcional ECOG: informe del caso de un paciente con cáncer de próstata en estadio IV resistente a la castración" "tienePdf" => "es" "tieneTextoCompleto" => "es" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "260" "paginaFinal" => "261" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Positive effect of Actinium 225-PSMA treatment on ECOG performance status: A case report on a patient with castration resistant stage IV prostate carcinoma" ] ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0005" "etiqueta" => "Figura 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 2292 "Ancho" => 1500 "Tamanyo" => 290954 ] ] "descripcion" => array:1 [ "es" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Paciente de 74 años con carcinoma de próstata metastásico, diagnosticado 4 años antes, y tratado con docetaxel y terapia hormonal. La figura muestra la gammagrafía ósea previa al tratamiento.</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "F. Novruzov, J.A. Aliyev, Z. Allahverdiyeva, E. Mehdi, F. Giammarile" "autores" => array:5 [ 0 => array:2 [ "nombre" => "F." "apellidos" => "Novruzov" ] 1 => array:2 [ "nombre" => "J.A." "apellidos" => "Aliyev" ] 2 => array:2 [ "nombre" => "Z." "apellidos" => "Allahverdiyeva" ] 3 => array:2 [ "nombre" => "E." "apellidos" => "Mehdi" ] 4 => array:2 [ "nombre" => "F." "apellidos" => "Giammarile" ] ] ] ] ] "idiomaDefecto" => "es" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "S2253808918300764" "doi" => "10.1016/j.remnie.2018.10.006" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2253808918300764?idApp=UINPBA00004N" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2253654X18301598?idApp=UINPBA00004N" "url" => "/2253654X/0000003800000004/v1_201906280916/S2253654X18301598/v1_201906280916/es/main.assets" ] ] "itemSiguiente" => array:19 [ "pii" => "S2253808919300679" "issn" => "22538089" "doi" => "10.1016/j.remnie.2019.05.002" "estado" => "S300" "fechaPublicacion" => "2019-07-01" "aid" => "1052" "copyright" => "Sociedad Española de Medicina Nuclear e Imagen Molecular" "documento" => "article" "crossmark" => 1 "subdocumento" => "fla" "cita" => "Rev Esp Med Nucl Imagen Mol. 2019;38:262-71" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:2 [ "total" => 4 "HTML" => 4 ] "en" => array:13 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Continuing Education</span>" "titulo" => "Cardiac sympathetic innervation scintigraphy with <span class="elsevierStyleSup">123</span>I-meta-iodobenzylguanidine. Basis, protocols and clinical applications in Cardiology" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => array:2 [ 0 => "en" 1 => "es" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "262" "paginaFinal" => "271" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Gammagrafía de inervación simpática cardiaca con <span class="elsevierStyleSup">123</span>I-metayodobencilguanidina. Fundamento, protocolos y aplicaciones clínicas en Cardiología" ] ] "contieneResumen" => array:2 [ "en" => true "es" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0005" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 805 "Ancho" => 1000 "Tamanyo" => 92887 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0015" class="elsevierStyleSimplePara elsevierViewall"><span class="elsevierStyleSup">123</span>I-MIBG cardiac scintigraphy. Anterior planar image of two patients (A and B) obtained with MEGP (left) and LEHR collimators (right). The first shows greater image quality.</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "I. Casáns-Tormo, A. Jiménez-Heffernan, V. Pubul-Núñez, R. Ruano-Pérez" "autores" => array:4 [ 0 => array:2 [ "nombre" => "I." "apellidos" => "Casáns-Tormo" ] 1 => array:2 [ "nombre" => "A." "apellidos" => "Jiménez-Heffernan" ] 2 => array:2 [ "nombre" => "V." "apellidos" => "Pubul-Núñez" ] 3 => array:2 [ "nombre" => "R." "apellidos" => "Ruano-Pérez" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S2253654X18303457" "doi" => "10.1016/j.remn.2019.01.001" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2253654X18303457?idApp=UINPBA00004N" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2253808919300679?idApp=UINPBA00004N" "url" => "/22538089/0000003800000004/v1_201907020628/S2253808919300679/v1_201907020628/en/main.assets" ] "itemAnterior" => array:19 [ "pii" => "S2253808918301083" "issn" => "22538089" "doi" => "10.1016/j.remnie.2018.10.016" "estado" => "S300" "fechaPublicacion" => "2019-07-01" "aid" => "1031" "copyright" => "Sociedad Española de Medicina Nuclear e Imagen Molecular" "documento" => "article" "crossmark" => 1 "subdocumento" => "sco" "cita" => "Rev Esp Med Nucl Imagen Mol. 2019;38:258-9" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:2 [ "total" => 2 "PDF" => 2 ] "en" => array:11 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Interesting images</span>" "titulo" => "Recurrent pancreatic adenocarcinoma depicted by <span class="elsevierStyleSup">18</span>F-Fluciclovine PET/CT imaging" "tienePdf" => "en" "tieneTextoCompleto" => "en" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "258" "paginaFinal" => "259" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Recidiva de adenocarcinoma pancreático detectada mediante PET/TC con <span class="elsevierStyleSup">18</span>F-Fluciclovina" ] ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0005" "etiqueta" => "Fig. 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 1237 "Ancho" => 2500 "Tamanyo" => 343638 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">(A) <span class="elsevierStyleSup">18</span>F-Fluciclovine anterior maximum intensity projection PET image with the tracer-avid lesion at mid-abdomen (arrow). (row B) Corresponding axial, sagittal and coronal fused PET/CT and (row C) CT images of the retroperitoneal/mesenteric mass (arrows).</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Ba D. Nguyen, Tolgay I. Ocal" "autores" => array:2 [ 0 => array:2 [ "nombre" => "Ba D." "apellidos" => "Nguyen" ] 1 => array:2 [ "nombre" => "Tolgay I." "apellidos" => "Ocal" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S2253654X18301732" "doi" => "10.1016/j.remn.2018.10.003" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2253654X18301732?idApp=UINPBA00004N" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2253808918301083?idApp=UINPBA00004N" "url" => "/22538089/0000003800000004/v1_201907020628/S2253808918301083/v1_201907020628/en/main.assets" ] "en" => array:15 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Interesting images</span>" "titulo" => "Positive effect of Actinium 225-PSMA treatment on ECOG performance status: A case report on a patient with castration resistant stage IV prostate carcinoma" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "260" "paginaFinal" => "261" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "Fuad Novruzov, Jamil A. Aliyev, Zeynəb Allahverdiyeva, Elnur Mehdi, Francesco Giammarile" "autores" => array:5 [ 0 => array:3 [ "nombre" => "Fuad" "apellidos" => "Novruzov" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] ] ] 1 => array:3 [ "nombre" => "Jamil A." "apellidos" => "Aliyev" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "aff0010" ] ] ] 2 => array:3 [ "nombre" => "Zeynəb" "apellidos" => "Allahverdiyeva" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">c</span>" "identificador" => "aff0015" ] ] ] 3 => array:3 [ "nombre" => "Elnur" "apellidos" => "Mehdi" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] ] ] 4 => array:4 [ "nombre" => "Francesco" "apellidos" => "Giammarile" "email" => array:1 [ 0 => "F.Giammarile@iaea.org" ] "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">d</span>" "identificador" => "aff0020" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">*</span>" "identificador" => "cor0005" ] ] ] ] "afiliaciones" => array:4 [ 0 => array:3 [ "entidad" => "Department of Nuclear Medicine, National Centre of Oncology, Baku, Azerbaijan" "etiqueta" => "a" "identificador" => "aff0005" ] 1 => array:3 [ "entidad" => "Department of General Surgery, National Centre of Oncology, Baku, Azerbaijan" "etiqueta" => "b" "identificador" => "aff0010" ] 2 => array:3 [ "entidad" => "Department of Medical Oncology, Central Clinic Hospital, Baku, Azerbaijan" "etiqueta" => "c" "identificador" => "aff0015" ] 3 => array:3 [ "entidad" => "International Atomic Energy Agency, Nuclear Medicine and Diagnostic Imaging Section, Vienna, Austria" "etiqueta" => "d" "identificador" => "aff0020" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor0005" "etiqueta" => "⁎" "correspondencia" => "Corresponding author." ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Efecto positivo del tratamiento con Actinio 225-PSMA sobre el estado funcional ECOG: Informe del caso de un paciente con cáncer de próstata en estadio IV resistente a la castración" ] ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0010" "etiqueta" => "Fig. 2" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr2.jpeg" "Alto" => 1163 "Ancho" => 3167 "Tamanyo" => 438819 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">Due to progressive disease, the patient received 2 cycles of targeted treatment with <span class="elsevierStyleSup">177</span>Lu-PSMA, for a total of about 15<span class="elsevierStyleHsp" style=""></span>GBq. The figure shows <span class="elsevierStyleSup">68</span>Ga PSMA-11 PET/CT scan prior to treatment, MIP (A), axial PET (B), axial CT (C), and axial fusion (D) images indicate multiple intense pathologic uptakes in lymph nodes (simple arrow), liver (dashed arrow) and bone (arrowhead).</p>" ] ] ] "textoCompleto" => "<span class="elsevierStyleSections"><p id="par0005" class="elsevierStylePara elsevierViewall">Prostate cancer is the third highest cause of cancer deaths and the most commonly found malignancy in males within economically developed countries.<a class="elsevierStyleCrossRef" href="#bib0020"><span class="elsevierStyleSup">1</span></a></p><p id="par0010" class="elsevierStylePara elsevierViewall">Prostate-specific membrane antigen (PSMA) is a unique target in metastatic castration resistant prostate carcinoma patients (mCRPC). PSMA is a good example of theranostic agent. Promising results obtained with Gallium-68 labelled PSMA Positron Emission Tomography/Computed Tomography (PET/CT) have been extensively studied for prostate cancer, particularly restaging in patients with biochemical relapse following treatment with curative intent.</p><p id="par0015" class="elsevierStylePara elsevierViewall">PSMA can also be used with therapy purposes. In particular, alpha-emitting radioisotope Actinium-225 is more effective than beta-emitting Lutetium-177, due to higher rates of double-strand DNA breaks in prostate cancer cells. It has less tissue penetration and minimal surrounded effects in PSMA-negative cells.<a class="elsevierStyleCrossRef" href="#bib0025"><span class="elsevierStyleSup">2</span></a></p><p id="par0020" class="elsevierStylePara elsevierViewall">However, limited data are available on the clinical efficacy and side effects of <span class="elsevierStyleSup">225</span>Ac-PSMA targeted radionuclide treatment in mCRPC patients.<a class="elsevierStyleCrossRef" href="#bib0030"><span class="elsevierStyleSup">3</span></a></p><p id="par0025" class="elsevierStylePara elsevierViewall">In our case, <span class="elsevierStyleSup">225</span>Ac-PSMA resulted in remarkable clinical and biochemical responses. It may be considered as a promising therapy and could improve the ECOG performance status of end-stage mCRPC patients.</p><p id="par0030" class="elsevierStylePara elsevierViewall">However, the results obtained do not allow to reach any conclusion since, unfortunately, due to the short follow up of the patient, the increase in the ECOG level could not be confirmed in a long period of time (<a class="elsevierStyleCrossRefs" href="#fig0005">Figs. 1–3</a>).</p><elsevierMultimedia ident="fig0005"></elsevierMultimedia><elsevierMultimedia ident="fig0010"></elsevierMultimedia><elsevierMultimedia ident="fig0015"></elsevierMultimedia><span id="sec0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0005">Source of foundation</span><p id="par0035" class="elsevierStylePara elsevierViewall">Science Development Foundation under the President of the Republic of Azerbaijan (Grant No. EIF-2014-9(24)-KETPL-14/13/3).</p></span></span>" "textoCompletoSecciones" => array:1 [ "secciones" => array:2 [ 0 => array:2 [ "identificador" => "sec0010" "titulo" => "Source of foundation" ] 1 => array:1 [ "titulo" => "References" ] ] ] "pdfFichero" => "main.pdf" "tienePdf" => true "NotaPie" => array:1 [ 0 => array:2 [ "etiqueta" => "☆" "nota" => "<p class="elsevierStyleNotepara" id="npar0005">Please cite this article as: Novruzov F, Aliyev JA, Allahverdiyeva Z, Mehdi E, Giammarile F. Efecto positivo del tratamiento con Actinio 225-PSMA sobre el estado funcional ECOG: Informe del caso de un paciente con cáncer de próstata en estadio IV resistente a la castración. Rev Esp Med Nucl Imagen Mol. 2019;38:260–261.</p>" ] ] "multimedia" => array:3 [ 0 => array:7 [ "identificador" => "fig0005" "etiqueta" => "Fig. 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 2292 "Ancho" => 1500 "Tamanyo" => 290954 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">74 y patient with metastatic prostate carcinoma, diagnosed 4 years before and treated with Docetaxel and hormonal therapy. The figure shows bone scan prior to treatment.</p>" ] ] 1 => array:7 [ "identificador" => "fig0010" "etiqueta" => "Fig. 2" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr2.jpeg" "Alto" => 1163 "Ancho" => 3167 "Tamanyo" => 438819 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">Due to progressive disease, the patient received 2 cycles of targeted treatment with <span class="elsevierStyleSup">177</span>Lu-PSMA, for a total of about 15<span class="elsevierStyleHsp" style=""></span>GBq. The figure shows <span class="elsevierStyleSup">68</span>Ga PSMA-11 PET/CT scan prior to treatment, MIP (A), axial PET (B), axial CT (C), and axial fusion (D) images indicate multiple intense pathologic uptakes in lymph nodes (simple arrow), liver (dashed arrow) and bone (arrowhead).</p>" ] ] 2 => array:7 [ "identificador" => "fig0015" "etiqueta" => "Fig. 3" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr3.jpeg" "Alto" => 1163 "Ancho" => 3167 "Tamanyo" => 401710 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">After the second cycle of <span class="elsevierStyleSup">177</span>Lu-PSMA, <span class="elsevierStyleSup">68</span>Ga-PSMA PET/CT control scan showed no response in lymph node lesions. Only one liver lesion disappeared, while the bone lesion increased. The patient was considered in stable disease after the treatment. MIP (A), axial PET (B), axial CT (C), and axial fusion (D) images indicate multiple intense pathologic uptakes in lymph nodes (simple arrow), liver (dashed arrow) and bone (arrowhead). In comparison with pre-treatment images only the liver lesion disappeared (dashed arrow), while the bone lesion increased (arrowhead). When <span class="elsevierStyleSup">225</span>Ac-PSMA treatment (8<span class="elsevierStyleHsp" style=""></span>MBq) was administered (about one month after the decision to treat), the patient was in ECOG stage IV, with a PSA level of 623.8<span class="elsevierStyleHsp" style=""></span>ng/mL. The thrombocyte count was 64,000 one day before treatment, after 5 days of the treatment the thrombocyte count has increased to 88,000. Fifteen days after the treatment, the PSA level got down to 476.3<span class="elsevierStyleHsp" style=""></span>ng/mL and ECOG performance status rise to more favourable stage III. No treatment-related toxicity occurred, but the patient passed away 45 days after treatment because of heart failure (that was diagnosed 2 years before).</p>" ] ] ] "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0015" "bibliografiaReferencia" => array:3 [ 0 => array:3 [ "identificador" => "bib0020" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Clinically localized prostate cancer: AUA/ASTRO/SUO Guideline. Part II: Recommended approaches and details of specific care options" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "M.G. Sanda" 1 => "J.A. Cadeddu" 2 => "E. Kirkby" 3 => "R.C. Chen" 4 => "T. Crispino" 5 => "J. Fontanarosa" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.juro.2018.01.002" "Revista" => array:5 [ "tituloSerie" => "J Urol" "fecha" => "2018" "volumen" => "199" "paginaInicial" => "990" "paginaFinal" => "997" ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib0025" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Prostate-specific membrane antigen for prostate cancer theranostics: from imaging to targeted therapy" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "F. Arsenault" 1 => "J.M. Beauregard" 2 => "F. Pouliot" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1097/SPC.0000000000000357" "Revista" => array:7 [ "tituloSerie" => "Curr Opin Support Palliat Care" "fecha" => "2018" "volumen" => "12" "paginaInicial" => "359" "paginaFinal" => "365" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/29939893" "web" => "Medline" ] ] "itemHostRev" => array:3 [ "pii" => "S1386505617300795" "estado" => "S300" "issn" => "13865056" ] ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib0030" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "PSMA-PET based radiotherapy: a review of initial experiences, survey on current practice and future perspectives" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "S. Zschaeck" 1 => "F. Lohaus" 2 => "M. Beck" 3 => "G. Habl" 4 => "S. Kroeze" 5 => "C. Zamboglou" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1186/s13014-018-1047-5" "Revista" => array:5 [ "tituloSerie" => "Radiat Oncol" "fecha" => "2018" "volumen" => "13" "paginaInicial" => "90" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/29751842" "web" => "Medline" ] ] ] ] ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/22538089/0000003800000004/v1_201907020628/S2253808918300764/v1_201907020628/en/main.assets" "Apartado" => array:4 [ "identificador" => "47121" "tipo" => "SECCION" "en" => array:2 [ "titulo" => "Interesting image" "idiomaDefecto" => true ] "idiomaDefecto" => "en" ] "PDF" => "https://static.elsevier.es/multimedia/22538089/0000003800000004/v1_201907020628/S2253808918300764/v1_201907020628/en/main.pdf?idApp=UINPBA00004N&text.app=https://www.elsevier.es/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2253808918300764?idApp=UINPBA00004N" ]
Consulte los artículos y contenidos publicados en éste medio, además de los e-sumarios de las revistas científicas en el mismo momento de publicación
Esté informado en todo momento gracias a las alertas y novedades
Acceda a promociones exclusivas en suscripciones, lanzamientos y cursos acreditados
The Revista Española de Medicina Nuclear e Imagen Molecular (Spanish Journal of Nuclear Medicine and Molecular Imaging), was founded in 1982, and is the official journal of the Spanish Society of Nuclear Medicine and Molecular Imaging, which has more than 700 members. The Journal, which publishes 6 regular issues per year, has the promotion of research and continuing education in all fields of Nuclear Medicine as its main aim. For this, its principal sections are Originals, Clinical Notes, Images of Interest, and Special Collaboration articles. The works may be submitted in Spanish or English and are subjected to a peer review process. In 2009, it became the leading Spanish journal in the field of Medical Imaging on having an Impact Factor , awarded by the Journal Citation Reports.
Science Citation Index Expander, Medline, IME, Bibliomed, EMBASE/Excerpta Medica, Healthstar, Cancerlit, Toxine, Inside Conferences, Scopus
See moreThe Impact Factor measures the average number of citations received in a particular year by papers published in the journal during the two preceding years.
© Clarivate Analytics, Journal Citation Reports 2022
SRJ is a prestige metric based on the idea that not all citations are the same. SJR uses a similar algorithm as the Google page rank; it provides a quantitative and qualitative measure of the journal's impact.
See moreSNIP measures contextual citation impact by wighting citations based on the total number of citations in a subject field.
See moreRevista Española de Medicina Nuclear e Imagen Molecular (English Edition)
¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?
Are you a health professional able to prescribe or dispense drugs?
Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos